Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Whitehawk Therapeutics Inc

WHWK ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Micro Cap Analyst: BUY

Last Close

$4.46

▼ -4.70%

Market Cap $254.26M · Vol 111.32K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$254.26M

Micro Cap

Div Yield

N/A

EPS Growth

-196.26%

YoY

RSI (14)

70.00

Momentum

Beta

0.82

vs Market

52W High

$5.48

18.61% below

52W Low

$1.59

180.50% above

Volume

111.32K

Avg 179.32K

P/B

0.84

Price-to-book

ROE

N/A

Return on equity

Free Float

80.07%

Public shares

Shariah Compliance8 STANDARDS

✗ Whitehawk Therapeutics Inc (WHWK) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does WHWK pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-6.30%

+17.06%

-12.55%

+56.49%

YTD

+84.30%

+175.31%

-25.04%

-86.67%

Financials & Valuation

TTM · Annual

Total Revenue	$7.15M
Net Income	$-20,596,000.00
Revenue Growth (YoY)	N/A
Gross Margin	89.36%
Operating Margin	-1,601.12%
Net Profit Margin	-288.26%
ROE	N/A
ROA · ROIC	-18.63% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	15.97
P/B	0.84
P/FCF	N/A
EPS Growth	-196.26%
Outstanding Shares	57.01M

Technical Indicators

50-Day SMA	$4.14
200-Day SMA	$3.42
RSI (14)	70.00
Beta	0.82
52-Week High	$5.48
52-Week Low	$1.59

Volume Today	111.32K
Avg Daily Volume (30D)	179.32K
Relative Volume	0.62x
Volatility (10D)	82.03
Volatility (30D)	60.61
Free Float	80.07%

Analyst Consensus

BUY

Current Price $4.46

Mean Target $7.50

52W Low$1.59 52W High$5.48

Current

Target

$1.59 $5.48

Current Analyst target

+68.16% upside potential · 8 analysts

Identifiers

ExchangeNasdaq

FIGIBBG002WN7DV9

ISINUS00032Q1040

CountryUnited States of America

Sub-IndustryBiopharmaceuticals

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

REGN Regeneron Pharmaceuticals Inc -0.31% 207940.KS Samsung Biologics Co Ltd -1.02% UCB.BR Ucb SA -3.10% CSL.AX CSL Ltd -0.74% BIIB Biogen Inc -0.39%

Company Profile

Whitehawk Therapeutics, Inc., formerly Aadi Bioscience, Inc., is a preclinical stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Its advanced three-asset antibody drug conjugate (ADC) portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. Its assets include HWK-007, HWK-016 and HWK-206. HWK-007 represents a differentiated opportunity to potentially be among the first next-wave ADCs in clinical development for high PTK7-expressing cancers. HWK-016 is the first ADC that targets the membrane-bound portion of MUC16, a glycoprotein often overexpressed in cancers of female origin. HWK-016 is being evaluated in IND-enabling studies. HWK-206 is designed to address the neuronal target, SEZ6, which is often overexpressed in cancers of neuroendocrine origin.